A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.
Kenneth Kehl, MD, MPH
Advertisement
Kenneth Kehl, MD, MPH, is a medical oncologist at Dana-Farber Cancer Institute.
Articles by Kenneth Kehl, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
5